Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADJUNCT Study
2025-521489-80-00Phase 2Completed
- Sponsor
- MEDSIR
- Start
- Dec 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of zimberelimab, domvanalimab and sacituzumab govitecan in breast cancer, sponsored by MEDSIR. Primary endpoint: Objective response rate (ORR). Started Dec 2025; status: completed.
02
Drugs
zimberelimabdomvanalimabsacituzumab govitecan
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2025-521489-80-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521489-80-00.